IASIS Molecular Sciences is pioneering a new class of permanently active antimicrobial materials designed to eliminate biofilm formation and stop pathogen growth on surfaces across healthcare, food production, and the built environment. As microbial contamination exacts huge global costs annually, existing antimicrobial technologies are outdated, toxic, largely ineffective and cannot address the growing problem. No new scalable solutions have emerged in more than two decades—until now.

The Solution — IONCLAD™ ANTIMICROBIALS

IASIS has developed IONCLAD™ ANTIMICROBIALS, a family of next generation, polyionic antimicrobial materials that are fully integrated into plastics, paints, and coatings. Unlike conventional surface treatments, IONCLAD™ antimicrobial materials permanently prevent biofilms from forming and remain active for the life of the product. Our technology incorporates commercially available starting materials, enabling low cost, high-volume, large-scale production.

We continue to expand the IONCLAD™ ANTIMICROBIALS platform, and while several formulations are developed or in active development, our current priority is advancing IONCLAD™ SILVER and IONCLAD™ COPPER.

IONCLAD™ antimicrobial materials have demonstrated superior performance against bacteria, fungi, and viruses. ASTM E2562-22 (Biofilm Prevention Testing) confirms potent, repeatable biofilm prevention, and IONCLAD™ COPPER formulations have shown efficacy against Coronaviruses, Influenza, and Norovirus surrogates. A Foley catheter incorporating IONCLAD™ SILVER is currently being manufactured at a large CMO. EPA submissions for multiple chemistries are underway.

Other IONCLAD™ ANTIMICROBIALS have been developed or are in development, with our current focus on IONCLAD™ SILVER and IONCLAD™ COPPER.

IONCLAD™ ANTIMICROBIALS:

• Scalable, non-toxic, permanently active antimicrobial material platform.

• Prevent biofilm formation for the life of the product.

• Are readily integrated into polymers, coatings, and paints.

• Are cost effective because they are made from commercially available ingredients (low cost).

• Compatible with molding, extrusion, coating, curing, and large-scale production.

• The time for the industry to shift to a new platform has arrived!

Market Opportunity

The Serviceable Available Market exceeds $29B, spanning antimicrobial food packaging, medical devices, and antimicrobial paints/coatings, with the global antimicrobial plastics market expected to reach $52B. Across all target industries, the total addressable market is over $463B. These markets are ripe for disruption given the absence of novel, scalable antimicrobial technologies for more than 20 years.

Traction and Validation

IASIS has secured more than $3M in competitive, non-dilutive grants from the CDC and DoD to advance its medical device and coatings platforms. Partnerships and advisors include leaders from Sherwin-Williams, University of Alabama, University of Utah, and key manufacturing and regulatory organizations. Our SOTERION™ Foley catheter—an insurance-reimbursable device—is positioned as the first commercial product built on the IONCLAD™ ANTIMICROBIALS platform.

Vision

At IASIS, we envision a world where hospitals, long-term care facilities, medical devices, food processing environments, and public infrastructure are inherently safer—where the materials themselves prevent infections. IONCLAD™ represents the long-overdue platform shift needed to protect patients, reduce healthcare costs, and eliminate biofilm-driven harm across industries.

“Microbes are unable to grow on our materials because the surfaces have proven to be hostile to their survival thus, preventing biofilm formation. Also, they are non-toxic and scalable - the tech is ready.”

David J. Vachon PhD., Founder of IASIS